Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
Main finding · Incident VFsResult — go to the resultHazard ratio 0.26 95% CI 0.09–0.73Authors' conclusion
In real-world clinical practice, bisphosphonates or denosumab might be effective in reducing the risk of VFs related to ADTs.
Study context
- Population
- Consecutive men with prostate cancer undergoing ADT; mean age 74.8 ± 6.9 years226 prospective + 62 controls
- Participants
- 98 / 55 / 73 / 62
- Exposure
- Bisphosphonates or denosumab vs vitamin D and calcium only, in men on ADT
- Bisphosphonatesn = 98
- Denosumabn = 55
- Vitamin Dn = 73reference
- Controln = 62
- Outcome
- Incident morphometric VFs
- Follow-up
- 26.1 ± 10.7 months (range 18-64)
Methodological detailsreal-world, consecutive patients
- Real-world
- Consecutive patients
Main finding
Incident VFs
Hazard ratio
0.26
95% CI 0.09–0.73
P = 0.01
Bisphosphonates + Denosumabvs Vitamin D
HR 0.26 (95% CI 0.09–0.73); P = 0.01
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Vitamin D | Control | P value |
|---|---|---|---|
| Incident VFs, prospective cohort vs controls | — not stated in the abstract | 29.0% | P < 0.001 |
| Incident VFs, vitamin D with calcium vs controls | 12.3% | 29.0% | P = 0.016 |
— not stated in the abstract
- Incident vertebral fracture (VFs), prospective cohort vs controls: Prospective cohort 7.1%
Original publication
Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study. Endocr Pract. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →